Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > COLUMN
COLUMN
-
Practice Makes Perfect - Even in Marketing!
August 19, 2019
-
Failing Isn’t the Issue. What You Do Next Is All that Counts
July 26, 2019
-
Big Question Mark to Pricey Drug Bashing
July 12, 2019
-
The Science Behind Stage Fright, and How You Can Overcome It
June 28, 2019
-
The Power in Teaching Your Team “How to Speak”
May 28, 2019
-
Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
-
No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
-
6 Core Elements of Recruitment Mastery
March 22, 2019
-
Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
-
Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
-
Expat Truths from the Japanese Medical Device World
December 3, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Finding Captains in Your Organization
October 12, 2018
-
Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
-
How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
-
Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
-
5 Billion Yen Blockbuster?
June 20, 2018
-
It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
-
Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…